Omnix Medical
Founded in 2015, Omnix Medical is a clinical-stage biopharmaceutical company dedicated to developing novel antibiotic agents to combat infections caused by drug-resistant bacteria. Their innovative technology focuses on natural antimicrobial peptides, engineered for therapeutic use, targeting severe hospital-acquired infections and addressing the urgent threat posed by multidrug-resistant pathogens. The company is building a pipeline of first-in-class anti-infectives designed to treat severe, potentially lethal infections associated with multi-drug resistances.
Industries
Nr. of Employees
small (1-50)
Omnix Medical
High-Tech Village Givat Ram Campus, Jerusalem Israel
Patents
Combination of antimicrobial peptides and antibiotic drugs for treating diseases
2020-08-18 • US-10745452-B2
View Details
Combination of antimicrobial peptides and antibiotic drugs for treating diseases
2020-08-18 • US-10745452-B2
View DetailsProducts
Lead systemically administered antimicrobial peptide candidate (intravenous)
A systemically administered peptide therapeutic candidate developed for intravenous treatment of severe infections caused by multidrug-resistant Gram-negative bacteria; characterized by engineered stability and a membrane-disrupting bactericidal mechanism. The program has progressed through Phase I safety/PK evaluation and regulatory interactions supporting advancement to Phase II.
Preclinical respiratory-targeted peptide candidate
A preclinical peptide candidate targeting Gram-negative pathogens associated with recurrent respiratory infections, designed for activity against pulmonary pathogens including Pseudomonas.
Preclinical GI/skin-targeted peptide candidate
A preclinical peptide candidate targeting gastrointestinal and skin infections, including pathogens where resistance is common.
Lead systemically administered antimicrobial peptide candidate (intravenous)
A systemically administered peptide therapeutic candidate developed for intravenous treatment of severe infections caused by multidrug-resistant Gram-negative bacteria; characterized by engineered stability and a membrane-disrupting bactericidal mechanism. The program has progressed through Phase I safety/PK evaluation and regulatory interactions supporting advancement to Phase II.
Preclinical respiratory-targeted peptide candidate
A preclinical peptide candidate targeting Gram-negative pathogens associated with recurrent respiratory infections, designed for activity against pulmonary pathogens including Pseudomonas.
Preclinical GI/skin-targeted peptide candidate
A preclinical peptide candidate targeting gastrointestinal and skin infections, including pathogens where resistance is common.
Expertise Areas
- Antimicrobial peptide therapeutics
- Platform-based peptide discovery and lead optimization
- Preclinical efficacy testing in vitro and in vivo
- CMC and intravenous formulation development for peptides
Key Technologies
- Antimicrobial peptides
- Host-defense peptide-inspired design
- Peptide chemical synthesis and cyclization
- Membrane-disrupting pore-forming mechanisms
Key People
News & Updates
Results from the first-in-human study of OMN6, a novel antimicrobial peptide for Acinetobacter baumannii, conducted in healthy volunteers.
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
The FDA granted fast-track designation for OMN6, highlighting the urgent need for novel antimicrobials against Gram-negative bacteria.
Announcement of FDA approval for a Phase II trial of OMN6, aimed at treating life-threatening infections caused by Acinetobacter baumannii.
An overview of the innovative technology behind Omnix Medical's antibiotic development, focusing on antimicrobial peptides.
The Indian Patent Office has issued a Notice of Allowance for Omnix Medical’s lead antimicrobial peptide for the treatment of multidrug-resistant bacteria.
Results from the first-in-human study of OMN6, a novel antimicrobial peptide for Acinetobacter baumannii, conducted in healthy volunteers.
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
The FDA granted fast-track designation for OMN6, highlighting the urgent need for novel antimicrobials against Gram-negative bacteria.
Announcement of FDA approval for a Phase II trial of OMN6, aimed at treating life-threatening infections caused by Acinetobacter baumannii.
An overview of the innovative technology behind Omnix Medical's antibiotic development, focusing on antimicrobial peptides.
The Indian Patent Office has issued a Notice of Allowance for Omnix Medical’s lead antimicrobial peptide for the treatment of multidrug-resistant bacteria.